

Is Apixaban still hard to find in 2026? Get the latest shortage update, pricing info, and tips for patients struggling to fill their prescription.
If you've had trouble filling your Apixaban prescription recently, you're not alone. Since generic Apixaban entered the market in late 2024, many patients have experienced inconsistent availability at their local pharmacies. Some weeks it's there, some weeks it's not — and for a medication you need to take every single day, that's unacceptable.
Here's the latest on the Apixaban supply situation in 2026 and what you can do to make sure you stay protected.
Technically, Apixaban has not been listed on the FDA's official drug shortage list. However, "not on the shortage list" doesn't mean "easy to find." The reality on the ground is more nuanced.
What's actually happening:
The bottom line: Supply is improving compared to early 2025, but pockets of scarcity persist — especially for specific generic manufacturers or in certain geographic areas.
Several factors are contributing to the ongoing availability challenges:
When a blockbuster drug like Eliquis goes generic, it doesn't happen overnight. Multiple manufacturers are competing for market share, wholesalers are adjusting their contracts, and pharmacies are figuring out which versions to stock. This transition typically takes 12–18 months to fully stabilize.
Apixaban is prescribed to millions of Americans for atrial fibrillation, DVT, PE, and post-surgical clot prevention. With the U.S. population aging, the number of patients needing anticoagulation therapy continues to grow year over year.
Generic medications often rely on active pharmaceutical ingredient (API) suppliers overseas. Any disruption — from regulatory inspections to shipping delays to raw material shortages — can ripple through the supply chain and affect what's on your pharmacy's shelf.
For a deeper look at the factors behind availability issues, see our article on why Apixaban is so hard to find.
One of the biggest developments for Apixaban patients in 2026 is the availability of lower-cost generic options:
For a complete breakdown of savings options, read our guide on how to save money on Apixaban.
The good news is that 2026 brings more choices than ever for Apixaban patients:
Several manufacturers now produce generic Apixaban, which means more supply in the pipeline and increasing competition that should continue to drive prices down. If one manufacturer's version is unavailable, your pharmacist can often substitute another.
If you're tired of the weekly pharmacy lottery, consider switching to a mail-order pharmacy through your insurance plan. You'll typically get a 90-day supply delivered to your door, often at a lower copay than monthly retail fills.
Services like Cost Plus Drugs, Amazon Pharmacy, and Honeybee Health offer competitive pricing on generic Apixaban and may have more consistent stock than your local retail pharmacy.
If you need Apixaban today, here's your action plan:
For more detailed tips, see our full guide on how to find Apixaban in stock near you.
The Apixaban supply situation in 2026 is improving, but it's not perfect yet. Generic availability is expanding, prices are dropping, and more pharmacies are building reliable stock. But some patients are still hitting roadblocks.
The most important takeaway: never stop taking your blood thinner without talking to your doctor. Apixaban carries a boxed warning about the increased risk of stroke and blood clots when the medication is stopped prematurely.
Stay proactive. Refill early. Use tools like Medfinder to stay ahead of supply issues. And if you need help, your doctor and pharmacist are your best allies.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.